On 28 May 2020, American Renal Associates Holdings, Inc. (NYSE: ARA) stock observed trading -53.41% off 52-week high price. On the other end, the stock has been noted 14.01% away from low price over the last 52-weeks. The stock disclosed a move of -5.78% away from 50 day moving average and -20.22% away from 200 day moving average. Moving closer, we can see that shares have been trading -4.31% off 20-day moving average. The one-month performance of stock was -13.19%.
American Renal Associates Holdings, Inc. (ARA) recently reported financial and operating results for the quarter and year ended December 31, 2019.
The Company also reported that Joseph (Joe) Carlucci has communicated his intention to retire as Chief Executive Officer of the Company by the end of 2020. The Board of Directors will initiate a process to identify a successor for Mr. Carlucci and will immediately engage an executive search firm to support the search. Mr. Carlucci plans to continue as CEO and Chairman until his successor has started and will assist in ensuring a smooth transition.
“After a 42-year career in the healthcare industry, I am announcing my intention to retire in 2020. Co-founding ARA about two decades ago has been the highlight of my career, and it has been a tremendous privilege to lead this organization and our exceptional team ever since. Recently, we provide high quality, clinically integrated care to over 17,300 patients in joint venture with 400 physicians in 246 dialysis clinics across 27 states, and I am so proud of the growth we’ve achieved,” Carlucci stated. “Now is the right time for a new leader who can build on our established foundation and further realize ARA’s growth opportunities in a way that still prioritizes our Core Values.”
Financial and operating highlights include:
Revenue: Patient service operating revenues for the fourth quarter of 2019 were $206.1M, a decrease of 0.8%, as contrast to $207.8M for the prior-year period, which was primarily Because of declines in commercial treatment rates, partially offset by a raise of 4.8% in the number of dialysis treatments. Patient service operating revenues for the year ended December 31, 2019 were $822.5M, a raise of 2.1%, as contrast to $805.8M for the prior-year period, which was primarily Because of a raise of 6.5% in the number of dialysis treatments, partially offset by adverse changes in commercial treatment rates.
Treatment Volume: Total dialysis treatments for the fourth quarter of 2019 were 628,817, representing a raise of 4.8% over the fourth quarter of 2018. Non-purchased treatment growth was 3.2%, and purchased treatment growth was 1.6% for the fourth quarter of 2019. Normalized total treatment growth was 6.0%, and non-purchased treatment growth was 4.4%, as contrast to the fourth quarter of 2018. Total dialysis treatments for the year ended December 31, 2019 were 2,460,710, representing a raise of 6.5% over the prior-year period. Non-purchased treatment growth was 4.5%, and purchased treatment growth was 2.0% for the year ended December 31, 2019. Normalized total treatment growth was 7.3%, and non-purchased treatment growth was 5.3%, as contrast to the prior-year period.
Clinic Activity: As of December 31, 2019, the Company provided services at 246 outpatient dialysis clinics serving 17,306 patients. During the year ended December 31, 2019, we opened seven de novo clinics, two of which were opened in the fourth quarter, purchased two clinics, and sold four clinics.
The USA based company American Renal Associates Holdings, Inc. moved with change of 2.88% to $6.43 with the total traded volume of 11477 shares in recent session versus to an average volume of 113.77K. ARA’s shares are at -25.24% for the quarter and driving a 0.48% return over the course of the past year and is now at -39.73% since this point in 2018.